Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXS NASDAQ:CLRB NASDAQ:NRBO NASDAQ:PDSB NASDAQ:REPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.15+22.4%$0.06$0.00▼$0.78$6.28M1.175,514 shs689 shsCLRBCellectar Biosciences$4.87-1.3%$8.24$4.36▼$94.50$8.81M0.51144,089 shs57,678 shsNRBONeuroBo Pharmaceuticals$0.69+8.2%$0.70$2.08▼$5.16$5.95M-0.2639,536 shs115,357 shsPDSBPDS Biotechnology$1.24-5.0%$1.46$0.85▼$4.42$56.45M1.21472,934 shs406,597 shsREPHRecro Pharma$1.73$1.38▼$3.79$117.93M1.08126,298 shs141,800 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%0.00%+259.10%+290.58%-37.91%CLRBCellectar Biosciences+1.65%+2.26%-55.09%-41.14%-93.01%NRBONeuroBo Pharmaceuticals+8.21%+4.41%-3.95%-49.93%-84.78%PDSBPDS Biotechnology-1.52%-2.69%-22.62%+26.21%-63.07%REPHRecro Pharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACLRBCellectar Biosciences2.5342 of 5 stars3.22.00.00.02.11.71.3NRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APDSBPDS Biotechnology2.0358 of 5 stars3.74.00.00.01.10.00.0REPHRecro PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals 0.00N/AN/AN/ACLRBCellectar Biosciences 2.33Hold$375.007,608.12% UpsideNRBONeuroBo Pharmaceuticals 0.00N/AN/AN/APDSBPDS Biotechnology 3.33Buy$9.00628.74% UpsideREPHRecro Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest REPH, PDSB, NRBO, CLRB, and ADXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/11/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.005/14/2025CLRBCellectar BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M1.94N/AN/A($2.06) per share-0.07CLRBCellectar BiosciencesN/AN/AN/AN/A$8.98 per shareN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/A$1.50 per shareN/APDSBPDS BiotechnologyN/AN/AN/AN/A$0.51 per shareN/AREPHRecro Pharma$75.36M0.00N/AN/A$0.90 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/AN/AN/AN/ACLRBCellectar Biosciences-$44.58M-$21.92N/AN/AN/AN/A-619.70%-158.04%8/13/2025 (Estimated)NRBONeuroBo Pharmaceuticals-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%8/12/2025 (Estimated)PDSBPDS Biotechnology-$37.61M-$0.94N/AN/AN/AN/A-150.59%-69.15%8/12/2025 (Estimated)REPHRecro Pharma-$11.37M-$0.31N/AN/AN/A-15.15%-56.66%-11.14%N/ALatest REPH, PDSB, NRBO, CLRB, and ADXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PDSBPDS Biotechnology-$0.25-$0.21+$0.04-$0.21N/AN/A5/13/2025Q1 2025CLRBCellectar Biosciences-$5.10-$3.90+$1.20-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/AN/AN/ACLRBCellectar BiosciencesN/A2.472.47NRBONeuroBo PharmaceuticalsN/A2.412.41PDSBPDS Biotechnology0.292.332.33REPHRecro Pharma2.273.242.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%CLRBCellectar Biosciences16.41%NRBONeuroBo Pharmaceuticals1.37%PDSBPDS Biotechnology26.84%REPHRecro Pharma62.34%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%CLRBCellectar Biosciences5.04%NRBONeuroBo Pharmaceuticals1.05%PDSBPDS Biotechnology9.20%REPHRecro Pharma14.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala Pharmaceuticals2042.63 million42.36 millionNot OptionableCLRBCellectar Biosciences101.81 million1.72 millionOptionableNRBONeuroBo Pharmaceuticals108.62 million8.53 millionNot OptionablePDSBPDS Biotechnology2045.71 million41.51 millionOptionableREPHRecro Pharma18556.42 million48.41 millionOptionableREPH, PDSB, NRBO, CLRB, and ADXS HeadlinesRecent News About These CompaniesPharma’s climate change vulnerability and opportunityJuly 19, 2024 | pharmaphorum.comPDorf Ketal's Indian unit acquires veterinary pharma brandApril 10, 2024 | vccircle.comVFuji Pharma Co. Ltd.January 30, 2024 | wsj.comAurobindo Pharma Q2 results: Net profit jumps 85% to Rs 757 croreNovember 22, 2023 | moneycontrol.comRetaining the human element of AI within pharma and healthcareNovember 21, 2023 | pharmaphorum.comPHere's what Wall Street expects from Recro Pharma's earnings reportNovember 7, 2023 | markets.businessinsider.comUS supreme court halts Purdue Pharma deal that shields Sacklers from lawsuitsAugust 16, 2023 | theguardian.comMankind Pharma share priceAugust 9, 2023 | livemint.comWhat Wall Street expects from Recro Pharma's earningsAugust 9, 2023 | markets.businessinsider.comMankind Pharma Ltd (MNKI)August 3, 2023 | investing.comEversana and Amazon plan generative AI push in pharmaJuly 30, 2023 | pharmaphorum.comPAurobindo Pharma Ltd.July 24, 2023 | ndtv.comNBaudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumpsJune 30, 2023 | bizjournals.comPharma reform: Patients can’t afford to wait. Act now.June 13, 2023 | politico.euPSun Pharma reports "information security incident"; isolates impacted IT assetsMarch 9, 2023 | health.economictimes.indiatimes.comWatch: Woody Harrelson Torches Big Pharma During Hilarious Opening Monologue on SNLMarch 1, 2023 | ijr.comIAurobindo Pharma shares gain even as Q3 profit sinks; board declares 300% dividendFebruary 17, 2023 | moneycontrol.comPaytm, Adani Enterprises, HUL, Sun Pharma, Lupin, Cummins, GAIL, Macrotech Developers stocks in focusDecember 20, 2022 | financialexpress.comFPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTLJune 24, 2022 | benzinga.comSocietal CDMO IncApril 20, 2022 | reuters.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeREPH, PDSB, NRBO, CLRB, and ADXS Company DescriptionsAyala Pharmaceuticals NASDAQ:ADXS$0.15 +0.03 (+22.36%) As of 03:41 PM EasternAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Cellectar Biosciences NASDAQ:CLRB$4.86 -0.07 (-1.32%) Closing price 03:58 PM EasternExtended Trading$4.86 0.00 (-0.10%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.NeuroBo Pharmaceuticals NASDAQ:NRBO$0.69 +0.05 (+8.21%) As of 07/9/2025NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.PDS Biotechnology NASDAQ:PDSB$1.24 -0.07 (-5.00%) Closing price 03:58 PM EasternExtended Trading$1.24 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.Recro Pharma NASDAQ:REPHRecro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
